Literature DB >> 8309625

A high frequency of apolipoprotein E4 isoprotein in Japanese patients with late-onset nonfamilial Alzheimer's disease.

A Ueki1, M Kawano, Y Namba, M Kawakami, K Ikeda.   

Abstract

Phenotypes of apolipoprotein E (apo E) were determined by the iso-electric focusing method in 42 Japanese patients with nonfamilial late-onset Alzheimer's disease (AD) and 96 age-matched controls without hyperlipidemia and/or diabetes. There was a striking difference in the distribution of apo E phenotypes between patients with AD and controls (P < 0.0001). Such a difference was mostly attributable to different frequencies of phenotypes E4/3 and E3/3. The apo E4/3 phenotype was detected in 24 (57.1%) of 42 patients with AD, more than six times oftener than in nine (9.4%) of 96 controls. In contrast, apo E3/3, which is the most common apo E phenotype in various ethnic groups, was detected in only 15 (35.7%) patients with AD. These results indicate a strong association between apo E4 isoprotein and Japanese late-onset nonfamilial AD, and that apo E4 is a possible risk factor for the development of this type of AD.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8309625     DOI: 10.1016/0304-3940(93)90373-s

Source DB:  PubMed          Journal:  Neurosci Lett        ISSN: 0304-3940            Impact factor:   3.046


  15 in total

1.  Reduction in amyloid A amyloid formation in apolipoprotein-E-deficient mice.

Authors:  M S Kindy; D J Rader
Journal:  Am J Pathol       Date:  1998-05       Impact factor: 4.307

Review 2.  Omega-3 fatty acids, lipids, and apoE lipidation in Alzheimer's disease: a rationale for multi-nutrient dementia prevention.

Authors:  Marcus O W Grimm; Daniel M Michaelson; Tobias Hartmann
Journal:  J Lipid Res       Date:  2017-05-20       Impact factor: 5.922

3.  Effect of apolipoprotein E allele epsilon4 on the initial phase of amyloid beta-protein accumulation in the human brain.

Authors:  M Morishima-Kawashima; N Oshima; H Ogata; H Yamaguchi; M Yoshimura; S Sugihara; Y Ihara
Journal:  Am J Pathol       Date:  2000-12       Impact factor: 4.307

Review 4.  Interaction of apolipoprotein E epsilon 4 with other genetic and non-genetic risk factors in late onset Alzheimer disease: problems facing the investigator.

Authors:  R Katzman; D Kang; R Thomas
Journal:  Neurochem Res       Date:  1998-03       Impact factor: 3.996

5.  Both targeted mass spectrometry and flow sorting analysis methods detected the decreased serum apolipoprotein E level in Alzheimer's disease patients.

Authors:  Sun-Ho Han; Jun Seok Kim; Youngju Lee; Heesun Choi; Jong-Won Kim; Duk Lyul Na; Eun Gyeong Yang; Myeong-Hee Yu; Daehee Hwang; Cheolju Lee; Inhee Mook-Jung
Journal:  Mol Cell Proteomics       Date:  2013-12-08       Impact factor: 5.911

6.  Neuronal apoptosis by apolipoprotein E4 through low-density lipoprotein receptor-related protein and heterotrimeric GTPases.

Authors:  Y Hashimoto; H Jiang; T Niikura; Y Ito; A Hagiwara; K Umezawa; Y Abe; Y Murayama; I Nishimoto
Journal:  J Neurosci       Date:  2000-11-15       Impact factor: 6.167

7.  The genetics of dementia.

Authors:  Janice L Farlow; Tatiana Foroud
Journal:  Semin Neurol       Date:  2013-11-14       Impact factor: 3.420

8.  Influence of apolipoprotein E genotype on senile dementia of the Alzheimer and Lewy body types. Significance for etiological theories of Alzheimer's disease.

Authors:  C R Harrington; J Louwagie; R Rossau; E Vanmechelen; R H Perry; E K Perry; J H Xuereb; M Roth; C M Wischik
Journal:  Am J Pathol       Date:  1994-12       Impact factor: 4.307

Review 9.  Apolipoprotein E and Alzheimer disease.

Authors:  W J Strittmatter; A D Roses
Journal:  Proc Natl Acad Sci U S A       Date:  1995-05-23       Impact factor: 11.205

10.  Apolipoprotein E is a kinetic but not a thermodynamic inhibitor of amyloid formation: implications for the pathogenesis and treatment of Alzheimer disease.

Authors:  K C Evans; E P Berger; C G Cho; K H Weisgraber; P T Lansbury
Journal:  Proc Natl Acad Sci U S A       Date:  1995-01-31       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.